Antigen-Specific Immunotherapy Technology (“Desense Technology”)
Tithon has been granted licenses to market and sell licenses to clinics and medical practices throughout the world (“Licensed Clinic Locations”), the Desense Technology, including all products, methods, processes and procedures for performing antigen-specific immunotherapy as a treatment for many autoimmune disorders, including multiple sclerosis (MS), type 1 diabetes, Graves’ disease and systemic lupus erythematosus (SLE). This involves the injection and oral administration of membranes of cells that cause autoimmune disease by dampening down their aggression against the body’s own tissues while converting them into cells capable of protecting against disease.
MEDICAL CONDITION ENQUIRY
For further information regarding a medical condition in which the Antigen-Specific Immunotherapy may be useful, contact us by completing and sending the following form, and we will contact you as soon as possible.